Opinion/decision on a Paediatric investigation plan (PIP): Stivarga, regorafenib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps), PIP number: EMA/PE/0000182170

Human medicines European public assessment report (EPAR): Tasigna, nilotinib, Date of authorisation: 19/11/2007, Revision: 48, Status: Authorised

EMA/PE/0000181778

Human medicines European public assessment report (EPAR): Rapiscan, regadenoson, Date of authorisation: 06/09/2010, Revision: 17, Status: Authorised

EMA/PE/0000181518

EMA/PE/0000181441

EMA/PE/0000221101

Opinion/decision on a Paediatric investigation plan (PIP): Trixeo Aerosphere, Budesonide,Formoterol (fumarate),glycopyrronium bromide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Respiratory, thoracic and mediastinal disorders, PIP number: EMA/PE/0000181335

EMA/PE/0000220986

Human medicines European public assessment report (EPAR): Datroway, datopotamab deruxtecan, Date of authorisation: 04/04/2025, Revision: 3, Status: Authorised